Painful diabetic neuropathy (PDN) afflicts more than three million people in the United States. It characterized by numbness, tingling, and burning, sharp, shooting or other painful sensations, commonly in the feet, legs, and/or hands. PDN is managed with multiple well-established, generic treatment options. Antidepressants (e.g., tricyclic antidepressants, serotonin / norepinephrine reuptake inhibitors), antiepileptic drugs (e.g., gabapentin), nonsteroidal anti-inflammatory drugs (NSAIDs), and opioid-based drugs are all used to treat PDN patients. However, current analgesics do not offer adequate pain relief, leaving unmet need and opportunity for new options, especially novel mechanisms of action, in this arena. The successful launch of a novel analgesic requires a granular understanding of treatment patterns in this crowded and highly generic market.
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.
Markets covered: United States
Key companies: Collegium Pharmaceuticals, Protega Pharmaceuticals, Averitas, Kowa, Azurity, Almatica
Key drugs: Gabapentin (Neurontin, generics), tramadol, duloxetine (Cymbalta, generics), pregabalin (Lyrica, generics), other antidepressants (e.g., amitriptyline, citalopram, escitalopram), other AEDS (e.g., carbamazepine, topiramate), oral NSAIDs, opioid analgesics (e.g., Belbuca, RoxyBond, Xtampza ER), Qutenza, Gralise, Horizant, Nucynta
The Treatment Algorithms dashboard is an interactive supplement to our PowerPoint-based claims data analysis reports and retains the full set of analyses included in the reports (i.e., newly diagnosed patients, recently treated patients, persistency, and compliance). The dashboard allows for easier navigation of data visualizations and provides more detailed analyses examining the flow of treatment regimens in newly diagnosed and recently treated patients.